Pfizer's Lorbrena, or lorlatinib, has received expanded FDA approval as treatment for metastatic non-small cell lung cancer in patients with anaplastic lymphoma kinase-positive tumors. The FDA also granted approval to Ventana Medical System's Ventana ALK (D5F3) CDx Assay for use as companion diagnostic test for Lorbrena.
FDA approves new indication for Pfizer's lorlatinib
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.